Web6 set 2024 · JCOG1213: Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine … Web21 mar 2024 · Phase 3, JCOG1213, TOPIC-NEC Etoposide and irinotecan showed equal efficacy in a head-to-head study among patients with advanced neuroendocrine …
教育担当: 国立がん研究センター 中央病院 共に肝胆膵難治がん …
Web6 set 2024 · JCOG1213: Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. 平易な研究名称 / Public Title(Acronym ... Web『消化管・肝胆膵原発の切除不能・再発神経内分泌癌(NEC)を対象としたエトポシド/シスプラチン(EP)療法とイリノテカン/シスプラチン(IP)療法のランダム化比較試験(JCOG1213)』 『切除不能または再発食道癌に対するCF(シスプラチン+5-FU)療法とbDCF(biweeklyドセタキセル+CF)療法のランダム化第III相比較試験(JCOG1314) … lower budget mean
【課題管理番号】 平成 29 年5月27 日 - AMED
WebUMIN-CTR Clinical Trial. Unique ID issued by UMIN. UMIN000014795. Receipt number. R000017173. Scientific Title. Randomized phase III study of etoposide plus cisplatin combination therapy versus irinotecan plus cisplatin combination therapy in advanced neuroendocrine carcinoma of the digestive system. (JCOG1213,TOPIC-NEC) Web8 ago 2014 · JCOG1213 Coordinating Office National Cancer Center, Tokyo Hepatobiliary and Pancreatic Medical Oncology: scientific contact: Name: Okusaka Takuji: Address: 5-1-1. Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan : Telephone (+81)03-3542-2511: E-mail: [email protected]: Affiliation: National Cancer Center, Tokyo Hepatobiliary and … Web23 gen 2024 · jcog1213: 消化管・肝胆膵原発の切除不能・再発神経内分泌癌(nec)を対象としたエトポシド/シスプラチン(ep)療法とイリノテカン/シスプラチン(ip)療法の … horror book title idea